{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T22:51:25Z","timestamp":1774479085048,"version":"3.50.1"},"reference-count":7,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>B\u2010cell prolymphocytic leukaemia (B\u2010PLL) is an aggressive B\u2010cell lymphoproliferative disease with few clinically proven targeted treatments. Due to the rarity of the condition, there is a paucity of clinical trial data and none that involve targeted inhibitors. We present a unique case of relapsed refractory B\u2010PLL treated to a sustained minimal residual disease\u2010negative remission with venetoclax monotherapy, to add to the current evidence base and rationale for future studies using BCL\u20102 inhibitors in B\u2010PLL.<\/jats:p>","DOI":"10.1111\/ejh.13837","type":"journal-article","created":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T17:57:42Z","timestamp":1658685462000},"page":"590-592","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Venetoclax induces deep and durable minimal residual disease\u2010negative remission in high\u2010risk <scp><i>TP53<\/i><\/scp> disrupted B prolymphocytic leukaemia"],"prefix":"10.1111","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0380-7112","authenticated-orcid":false,"given":"Lucia Y.","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital Oxford University Hospitals NHS Foundation Trust  Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-9749","authenticated-orcid":false,"given":"Toby A.","family":"Eyre","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital Oxford University Hospitals NHS Foundation Trust  Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.8.658"},{"issue":"21","key":"e_1_2_6_3_1","first-page":"1821","article-title":"Genetic characterization of B\u2010cell prolymphocytic leukemia: a prognostic model involving MYC and TP53","volume":"134","author":"Chapiro E","year":"2019","journal-title":"Blood"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15151"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15912"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25733"},{"issue":"16","key":"e_1_2_6_7_1","first-page":"100266","article-title":"Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax","volume":"30","author":"Siddiqui MT","year":"2021","journal-title":"Leuk Res Rep"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1689392"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13837","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13837","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13837","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T09:00:40Z","timestamp":1692694840000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":7,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1111\/ejh.13837"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13837","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"assertion":[{"value":"2022-04-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}